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Akshay A Desai 
DATA ANALYSIS AND CREATION OF EPIGENTICS DATABASE 
Abstract 
 This thesis is aimed at creating a pipeline for analyzing DNA methylation 
epigenetics data and creating a data model structured well enough to store the analysis 
results of the pipeline. In addition to storing the results, the model is also designed to 
hold information which will help researchers to decipher a meaningful epigenetics sense 
from the results made available. Current major epigenetics resources such as PubMeth, 
MethyCancer, MethDB and NCBI’s Epigenomics database fail to provide holistic view of 
epigenetics. They provide datasets produced from different analysis techniques which 
raises an important issue of data integration. The resources also fail to include 
numerous factors defining the epigenetic nature of a gene. Some of the resources are 
also struggling to keep the data stored in their databases up-to-date. This has 
diminished their validity and coverage of epigenetics data. In this thesis we have tackled 
a major branch of epigenetics: DNA methylation. As a case study to prove the 
effectiveness of our pipeline, we have used stage-wise DNA methylation and expression 
raw data for Lung adenocarcinoma (LUAD) from TCGA data repository. The pipeline 
helped us to identify progressive methylation patterns across different stages of LUAD. It 
also identified some key targets which have a potential for being a drug target. Along 
with the results from methylation data analysis pipeline we combined data from various 
online data reserves such as KEGG database, GO database, UCSC database and 
BioGRID database which helped us to overcome the shortcomings of existing data 
collections and present a resource as complete solution for studying DNA methylation 
epigenetics data.       
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Chapter 1 Introduction 
1.1 What is Epigenetics? 
The genotypic make up of monozygous twins is identical. However, a study[1] on 
monozygous twins proved that they are not identical as they do not show same disease 
susceptibility. The study also observed that this deviation in susceptibility increases with 
the ageing of twins. Now the cause of most diseases is attributed to the alteration in the 
expression level of genes. This alteration affects the normal functionality of the protein 
machinery involved in the concerned affected biological process, hence the disease. In 
monozygotic twins if the genetic makeup is not altered than what are the possible 
reasons for the variation in disease susceptibility? What are the factors responsible for 
affecting the gene expression levels other than mutations in DNA sequences? A 
substantial part of these questions is answered by a new field called “Epigenetics”. 
Epigenetics was first defined by Conrad Waddington in 1940. According to 
Conrad Waddington epigenetics is “the interactions of genes with their environment 
which bring the phenotype into being”. As biological terms have different meanings for 
different people[2], epigenetics is no exception to this tradition. In contrast to Conrad’s 
definition, Arthur Riggs et al defined epigenetics as “the study of mitotically and/or 
meiotically heritable changes in gene function that cannot be explained by changes in 
DNA sequence”[3]. The two definitions mentioned explain important aspects of 
epigenetics but do not cover the field in totality. One definition explains epigenetics from 
a developmental biologist perceptive and the other one defines what epigenetics is not 
i.e. an inheritance of mutations. But the definition from an article[2] in nature very well 
summarizes the concept. It states that epigenetics is “the structural adaptation of 
chromosomal regions so as to register, signal or perpetuate altered activity states”.   
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Epigenetics marks determine the functional output of the information that is 
stored in the genome. These marks are the link between prenatal and postnatal 
exposures and the phenotypic changes happening later in life. This connection is 
beautifully explained by a BBC T.V science programme. It states that “at heart of this 
new field is a simple but contentious idea- that genes have ‘memory’. That the lives of 
your grandparents - the air they breathed, the food they ate, even the things they saw - 
can directly affect you, decades later, despite your never experiencing these things 
yourself. And that what you do in your lifetime could in turn affect your grandchildren.” 
Epigenetics tries to explain genes beyond the DNA. The word epigenetics also literally 
means ‘above the genetics’ which is now often used to explain gene expression changes 
that occur without the change in DNA sequence. It explains the heritable changes in 
gene expression or cellular phenotype caused by the factors other than changes in DNA 
sequences. These factors could be nutrition, stress or other environmental influences 
which causes a gene to turn on or off. These changes may remain through cell divisions 
for the remainder of the cell’s life and may also last for generations. However, there is no 
change in the underlying DNA sequence of the organism; instead, non-genetic factors 
cause the organism’s genes to behave differently.  
DNA methylation and histone modification are the two important molecular 
mechanisms playing a major role in epigenetic regulation of genes[4]. These 
modifications affect both DNA and chromatin.   
1.2 Important parts of epigenetic machinery. 
Most widely studied phenomenon related to epigenetics is DNA methylation. 
DNA methylation occurs at the carbon-5 position of cytosine in CpG dinucleotides. 
Histone modifications is the next most common phenomenon studied related to 
epigenetics. Histone modifications are the post-translational modifications which cause 
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the changes to the chromatin packaging of DNA. Apart from these two commonly 
studied mechanisms other epigenetic controls include regulation by microRNAs which 
are non-coding RNAs and processes that manage higher-level packaging of chromatin 
within the nucleus. 
There are regions in human genome with more than 200 bases which consist of 
at least 50% G+C content and at least 0.6 ratio of observed to statistically expected CpG 
frequencies. These CpG dinucleotides clusters are called CpG islands. The “p” in CpG 
stands for “phosphodiester bond”. This bond is present between cytosine and guanine 
which are the “C” and “G” in CpG. Cytosine methylation is the most extensively studied 
phenomenon in context with epigenetic modifications. Modifications in the methylation 
state of CpG island are epigenetically important because about 60% of human gene 
promoters are associated with CpG islands. These promoter regions are usually un-
methylated in normal cells but nearly 6% of them become methylated. This methylation 
occurs in a tissue-specific manner during early development or in different tissues[5]. 
CpG-island methylation is commonly associated with silencing of genes which causes 
the reduction in the expression level of these genes. This kind of methylation is the only 
epigenetic modification that directly affects the DNA, hence the name “DNA 
methylation”. DNA methylation causes the replacement of hydrogen atom of the cytosine 
base by a methyl group which affects the accessibility of transcription binding sites thus 
causing the silencing of genes. In cancer, epigenetic modification due to DNA 
methylation causes the silencing of tumor suppressing genes. 
Histone modification is another important epigenetic factor. Nucleosome at the 
core contains a histone octamer comprising of 2 copies each of H2A, H2B, H3 and H4. A 
DNA of 147-bp segment is wrapped around the histone octamer in 1.65 turns. 
Neighboring nucleosomes are separated by a ~50 bp of DNA. H1 is the histone which 
binds to the linker DNA, binding off the nucleosome at the location where DNA enters 
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and leaves, hence it is called the linker histone. The core histones are modified at their 
amino-terminal tails by acetylation, phosphorylation, methylation and ubiquitylation. 
These modifications play an important role in gene regulation by defining the gene 
activity based on the combined acetylation, phosphorylation and methylation status and 
occur mostly post-transcriptionally.  
There are 3 classes of chromatin-remodeling proteins in mammalian cells. These 
complexes are SWI/SNF/Brm, ISWI and Mi-2/NuRD and contain different catalytic 
ATPase subunits with associated proteins. The enzymes involved in chromatin-
remodeling use the ATP hydrolysis energy to influence the structure of nucleosome and 
the DNA wrapped on it. Such influence of these proteins affects the accessibility of 
chromatin to various chromatin proteins that control transcription, DNA replication, 
recombination and other biological processes.      
1.3 Epigenetics: Hope for Cancer cure. 
Global changes in DNA methylation, histone modification and chromatin-
modifying enzyme expression profiles characterizes the cancer epigenome[6]. Cancer 
cells acquire a specific hypomethylation and hypermethylation patterns at the CpG 
islands of the promoter regions of genes. Hypomethylation at promoter regions of 
oncogenes activates their aberrant expression while hypermethylation at promoter 
regions leads to inactivation of tumor suppressor genes. Chromosomal instability, 
translocations and gene disruption is caused by the global hypomethylation at repetitive 
sequences[7]. Hypomethylation in the promoter regions of genes like S100P in 
pancreatic cancer, SNCG in breast and ovarian cancers and MAGE and DPP6 in 
melanomas is a well-studied phenomenon. Hypermethylation on the other hand is 
mainly observed at specific CpG islands and affects genes involved in the main cellular 
  
5 
  
pathways like DNA repair, vitamin response, Ras signaling, cell cycle control, p53 
network and apoptosis.  
In cancer cells a global reduction of mono-acetylated H4K16 is observed as an 
important histone modification. This loss in acetylation is mainly due to the 
overexpression of entities belonging to Sirtuin family of proteins[8]. Apart from the global 
loss of H4K16, there is a variation in the distribution of the histone methyl marks in 
cancer cells that is observed. This variation is mainly caused due to the alteration in the 
expression of histone methyltransferases and demethylases. Histone phosphorylation, 
too, according to current studies is found to be relevant for cancer studies. JAK2, a non-
receptor tyrosine kinase, is involved in hematological malignancies by getting activated 
through chromosomal translocations and point mutations. In addition to methylation and 
histone modifications, all families of chromatin remodelers are associated with cancer. 
Promoter hypermethylation of MLH1 in colon cancer is observed which proves the 
involvement of nucleosome remodeling in the transcriptional down regulation by 
promoter hypermethylation.     
Epigenetic therapy is targeted towards reprogramming the network of chemical 
changes that alter the functioning of cancer cells DNA rather than destroying them by 
disrupting their DNA or affecting important cancer pathways. The possibility for therapy 
has arisen due to the reversible nature of epigenetic changes. Hence the main aim of 
therapy is to restore ‘normal epigenome’. The first epigenetics drugs to be proposed for 
cancer treatment are DNA methylation inhibitors. Drugs such as 5-Aza-CR (azacitidine) 
and 5-aza-CdR (decitabine) which are DNA methylation inhibitors are approved by FDA 
for treating myelodysplastic syndromes[9]. A recent clinical trial conducted by 
researchers at John Hopkins institute proved the effectiveness of low-dose azacitidine 
combined with entinostat which is another epigenetic drug, for treating patients with 
advanced lung cancer. Apart from lung cancer the team also proved the effectiveness of 
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low doses of these drugs with antitumor effects in cell lines and in mouse models for 
different cancers such as leukemia, breast and colon cancer. 
Often loss of histone acetylation is also attributed to the aberrant gene silencing 
in cancer. HDAC inhibitors have been proved to demonstrate anti-tumorigenic effects 
which include activities such as growth arrest, apoptosis and the induction of 
differentiation. These inhibitors help in re-establishing the normal histone acetylation 
patterns and reactivating silenced tumor suppressor genes[10]. Suberoylanilide 
hydroxamic acid (SAHA) is one such HDAC inhibitor which has been proved for its use 
in clinic for treating T cell cutaneous lymphoma. Combinatorial cancer treatment 
strategies have also been explored which includes use of both DNA methylation and 
HDAC inhibitors for treating cancer. The study exploring the combinatorial effects 
showed that the activation of certain tumor suppressor genes was seen only when 5-
Aza-CdR was administered in combination with trichostatin A. A combination of 5-Aza-
CdR also enhanced the anti-tumorigenic activity of depsipeptide on leukemic cells. 
Similar combinatorial effect was observed when phenyl-butyrate and 5-Aza-CdR where 
used together to demonstrate the reduction of lung tumor formation in mice. Apart from 
DNA methylation and HDAC inhibitors, HMT inhibitors and miRNAs are also explored for 
epigenetic therapy and hold a great potential. Thus epigenetics has defined a new way 
and inculcated a hope in the war against cancer. It has provided a fresh approach in 
understanding the underlying principle for cancer treatment.          
1.4 Network Biology 
A systematic catalogue of all molecules and their key interactions in a desired 
cellular system is important for any post-genomic biomedical research. Need to 
understand the interactions between these molecules and the functionality of these 
interactions lead to the development of “network biology” field. The advances in network 
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biology have helped to build new conceptual framework that has revolutionized our 
understanding about the biology and disease pathologies. It has been well established 
now that a complex interaction between different cellular components such as proteins, 
DNA, RNA and small molecules define a biological characteristic. Thus it is important to 
understand the dynamics and structure of complex intercellular interactions that are the 
underlying principles in formation of structure and function of a living cell.  
Current high-throughput data analysis techniques for understanding epigenetic 
processes generate different types of interactions which include types such as protein-
protein interaction, metabolic, signaling and transcription-regulatory networks. Each 
molecule is represented as a node in the network while the interactions between 
different molecules are represented by the edges of a network. A network of these 
networks helps us to understand the behavior of cell. Network biology quantifies different 
aspects of a given biological network which helps to characterize various biological 
systems. Following are some of the important network measures that let us compare 
and characterize different complex networks: 
a. Degree: The degree of a node in a network is defined as the number of connections 
or edges the node has to other nodes. In a directed network every node has two types of 
degrees; in-degree and out-degree. In-degree defines the number of incoming edges 
while the out-degree defines the number of outgoing edges.  
b. Degree distribution: It is the fraction of nodes in the network with degree k. Thus, the 
degree distribution P (k) is calculated by obtaining the nodes with degree k and dividing 
by the total number of nodes. This kind of distribution allows differentiation between 
different classes of the network.  
c. Shortest path and mean path length: Shortest path is the path with the smallest 
number of links between any selected nodes which are the nodes of interest. Whereas 
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mean path length is the average of the shortest paths between all pairs of nodes and 
provides a measurement which facilitates the overall network navigability. 
d. Clustering coefficient: It is defined as the measure which helps to calculate the degree 
to which nodes in a graph tend to cluster together. 
 Network biology has become an integral part of any biological data analysis. It 
has helped to understand various complex biological machineries and produce some 
important inference mechanisms. The field has great potential to interpret epigenetic 
data which is been generated now-a-days using different high-throughput processes. 
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Chapter 2 Background 
2.1 Current approaches for analyzing epigenetic data. 
A genome wide mapping of epigenetic information is done by using techniques which 
use a three-stage design. In first stage epigenetic information is obtained by 
biochemically converting it into genetic information. This conversion is achieved by 
enriching specific genomic regions which show aberrant epigenetic modifications. 
Second stage involves employment of high-throughput data generation techniques such 
as microarray and sequencing techniques. These techniques generate data which help 
to interpret epigenetic modifications and make a scientific prediction or analysis of the 
process. The third stage includes computational algorithms to make actual inference 
from the data generated from microarray and sequencing methods. 
Bisulphite treatment of DNA is the popular method for detecting DNA methylation. It 
reproducibly alters un-methylated cytosines to uracil, leaving methylated cytosines 
unchanged. This resolution of treatment yields single-nucleotide resolution information 
about the methylation status of a sequence of DNA. In addition combining this 
methodology with sequencing technologies and amplifying it with methylation-specific 
PCR allows investigating DNA methylation even at low quantities. Techniques such as 
ChIP-on-chip which are based on chromatin immunoprecipitation have recently made a 
major contribution in epigenomics profiling of cancer cells. Identification of histone 
modification is more challenging compared to DNA methylation assay[6]. The standard 
technique for finding histone modification is mass spectrometry but the technique is 
complex and difficult to implement genome-wide. ChIP-on-chip with genomic platforms is 
also used for analyzing histone modification data.         
Projects such as AHEAD Task, ENCODE Project, HEP Project Consortium have 
developed ground breaking techniques which have improved large-scale experimental 
  
10 
  
methods and have introduced new bioinformatic methods for analyzing epigenetic data 
generated by the methods. One of the projects ENCODE which was aimed to mapping 
functional elements in the human genome has greatly contributed in standardizing the 
epigenome data analysis process. The first step in the process involves unsupervised 
segmentation of chromatin data which is based on the wavelet smoothing and hidden 
Markov models[11]. The second step is the joint statistical analysis on the datasets from 
ENCODE pilot phase. This is an exploratory procedure on a large and heterogeneous 
datasets which hold a good amount of epigenetic information. Third step included 
annotation of functional promoters using alternative prediction methods which were 
developed and evaluated for the project. This step proves the ability of epigenetic data to 
improve the accuracy of promoter annotation. Fourth the overlap between two sets of 
genomic features is assessed by determining the significance of overlap by the statistical 
test developed by the researchers working in ENCODE project. This statistical test helps 
them to evaluate the significance of overlap between regions such as CpG islands and 
un-methylated genomic regions. The test also helps to obtain more realistic P-values 
compared to other randomization-based methods which give an over-estimated 
significance[11]. Fifth the epigenome datasets from the ENCODE project are 
incorporated into UCSC Genome Browser. UCSC genome Browser provides 
visualization and retrieval of these genomic and epigenomics datasets. Thus, these are 
the steps that were standardized by ENCODE project for analyzing epigenomics data. 
In addition to the techniques mentioned, bioinformatics methods like text mining and 
data mining combined with system’s biology also play an important role in analyzing 
epigenomics data. These techniques are widely used for downstream filtering, 
processing and annotation of the data.         
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2.2 Available epigenetic data resources: Features and Limitations 
 
Figure 1: PubMeth results for querying with specific cancer type 
 
PubMeth, MethyCancer, MethDB and NCBI’s Epigenomics database are the main 
data resources that are currently available providing useful information for epigenetic 
research. PubMeth is a database consisting of genes which are found to be methylated 
in specific cancer types. It is a cancer methylation database using text-mining from 
Medline/PubMed abstracts in addition to manual reading and annotation of preselected 
abstracts for extracting methylated genes[12]. The interface is designed to rank, 
summarize and present data in such a way that the information present in database is 
easily accessible. In PubMeth database a query can be either genes based or can be 
cancer type based. Thus PubMeth tries to collect information on methylated genes in 
different cancer types from all possible available literature data and provides an interface 
which summarizes the collected data. 
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Figure 2 Search panel for MethyCancer database 
 
MethyCancer is a database holding information on the relationship between DNA 
methylation, gene expression and cancer. This interplay between different facets of 
epigenetics is made available in the database through integration of large-scale data, its 
production and mining. The main data sources for the database are public resources 
which are accompanied by manual curation of the data obtained. In addition to public 
sources, the Cancer Epigenome Project in China also acts as a major contributor of 
experimental data to the database. Database holds 4 main types of data: CGI clones 
and global CGI predictions, DNA methylation data, cancer information, genes and 
mutations and correlation among DNA methylation, gene expression and cancer[13].  
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Figure 3 Search panel for MethDB database 
 
DNA methylation data for the database is collected from MethDB, HEP and Methylation 
Landscape of Human Genome at Columbia University (Columbia)[14].              
MethDB database stores information related to the degree of methylation in total 
DNA, DNA fragments and single nucleotide positions[15]. It also contains data on the 
nature and origin of the samples along with data obtained from the experiments. It 
provides a graphical and alphanumeric representation of methylation patterns and 
profiles helping in bringing the heterogeneous data on DNA methylation under one 
destination. The entries present in the database are cross-linked to other databases by 
including hyper-links to external data resources. Results received from database are 
distinguishable into 3 forms: methylation content, methylation profile and methylation 
pattern.       
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Figure 4 Search panel for Epigenomics database 
 
NCBI’s Epigenomics database is constructed by picking epigenetics oriented data 
from data archives like Gene Expression Omnibus and Sequence Read Archives[16]. 
Epigenetic data collected is then put to review, annotation and reformation. The raw data 
is processed by mapping it to generate genomic coordinates. These genomic 
coordinates are used to build genomic tracks which are used for visual representation of 
the data. The coverage of Epigenomics database currently covers data tracks for DNA 
methylation, histone modification, expression of small non-coding RNAs and chromatin 
accessibility. Transcription factors, components of the core machinery and histone 
modifying enzymes which are considered as chromatin associated factors are also made 
available through the database. ‘Studies’ and the ‘samples’ are two basic types of 
records in Epigenomics database.        
    Even though the above mentioned databases cover important epigenetic data, 
they fail to provide a universal view of epigenomics. PubMeth database does not cover 
all genes responsible for epigenetic modifications. Text-mining sources for the database 
are restricted to the abstracts from PubMed and Medline which does not include the 
complete set -+of literature that is present for epigenetics. Apart from text-mining related 
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statistics the database has no extra information related to epigenetics associated genes. 
It also fails to provide quantitative measures for DNA methylation levels. MethDB only 
focuses on DNA methylation whose information is general and sample oriented. In 
addition to this it is not optimized to cancer related queries either. MethyCancer also as 
an epigenetic database fails to answer every aspect of epigenomics modification. The 
data present in the database is not updated and the interface provides a complicated 
view which makes it difficult to query the database. NCBI’s Epigenomics primary data 
sources are GEO and SRA which inhibits database to contain complete data related to 
epigenetics. Considering the shortcomings and pitfalls of current epigenetic data 
resources there is a need for new data reserve which will have a greater coverage of the 
data and has information for better understanding the field. 
2.3 Thesis Statement 
Currently all major epigenetic databases lack in terms of the coverage of data stored 
in them and further these databases fail to undertake a universal data processing 
methodology. Each database has its own data processing pipeline which mostly focuses 
on cell lines rather than cancer and their sub-types as whole. They lack information 
which would help to provide a full epigenetic view for given components of the 
machinery. Most of the databases also fail to provide information on environmental 
factors which play a pivotal role in defining the epigenomics landscape. There is also a 
poor mapping or association between epigenetically affected genes and their role in 
major cancer pathways. Considering these shortcomings led to the idea of building a 
standard pipeline for analyzing epigenetic data and building a robust but universal data 
model which will house the data processed from this pipeline. 
This thesis mainly focuses on DNA methylation aspect of epigenetics as it has the 
major contribution in observed and cancerous epigenetic aberrations. We have built a 
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robust pipeline for processing the DNA methylation data obtained from ‘The Cancer 
Genome Atlas (TCGA)’ (http://cancergenome.nih.gov/). The pipeline processes the 
methylation data for different patients from TCGA using various statistical concepts and 
combines system biology[17] to make meaningful sense from the results obtained. Each 
cancer methylation data is processed stage-wise so the pipeline provides granularity in 
understanding the process as well helps to have a high level comparative view to 
understand the progression of methylation across different stages of cancer. Finally the 
results obtained from this pipeline are dumped into a database modeled to hold 
information for each cancer, stage-wise, and provide epigenetic attributes such as 
environmental factors, pathways, protein-protein interactions which help to understand 
the methylation state of a gene and its effect on other important cellular mechanisms. 
The scope and importance of pipeline is proved by using ‘Lung Adenocarcinoma 
(LUAD)’ as a case study. Lung cancer is one of the most common cancers. In United 
States 226,160 new cases were expected to be diagnosed in 2012 
(http://www.cancer.gov/cancertopics/types/lung). Lung cancer is morphologically divided 
into non-small cell (NSCLC) and small cell (SCLC)[18]. Lung adenocarcinoma (LUAD) is 
currently the most common of the lung cancers in both smokers and non-smokers. We 
have analyzed the DNA methylation data for different patients from TCGA repository and 
have provided a stage-wise result set. Using system’s biology we have obtained 
methylation patterns for LUAD across its different stages. These results are stored along 
with the stage-wise results for other cancers in our epigenetic database. Our database 
helps researchers to make epigenetic sense from the data made available to them.      
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Chapter 3 Methods 
3.1 Analysis Pipeline 
In order to understand a methylation data for a particular cancer in stage specific 
manner, the analysis pipeline was divided into following sections: 
Section1. Identification of significant genes from expression data 
The level 3 data available from TCGA was segregated based on the stages 
provided in Metadata. If 65% of the data for  a gene was log2  ≥ 1.4 or ≤ -1.4 , then the 
gene was considered for further analysis as it obeyed the stringency with respect to fold 
change > 2.5 (a log2 ratio of 1 represents a 2-fold change) [19].  The average value for 
each gene was then computed and considered for the next level analysis. If a gene was 
represented by two or more probes, then the median of its expression value was used.   
Section2. Identification of significant DNA Methylated genes from methylation 
data 
The beta-values [20], for normal and disease samples were downloaded from the 
TCGA for Illumnia HumanMethylation27 and stratified by stage. The difference between 
the normal and the disease beta-values were then calculated.  Genes with beta-values 
greater than 0.25 were considered hypermethylated and those with beta-values less 
than -0.25 were considered hypomethylated [20]. Using the Mann-Whitney U test [21], p-
values were computed for each gene. This test was considered as it can handle 
variance for unequal sample sizes. For the study the analysis of q-value and 1% FDR 
gave threshold for the p-values for all the stages[22]. Our analysis identified p-value < 
0.001, as the optimal threshold across all the stages. These genes were termed as 
“Significant DNA methylated genes”. Since the sample sizes were small, to get true 
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inferences resampling technique was performed. The samples were permuted large 
number of times (1000) and Mann Whitney Test was performed for each permuted 
samples and p-values were computed[23]. 
The DNA methylated genes were then annotated with pathway information using 
KEGG [24]. This information was used to understand the stage-wise profile of pathways 
consisting of DNA methylated genes. This analysis found common and unique pathways 
across stages. One of the limitations of the pathway analysis was that the analysis was 
limited to the mapping of DNA methylated genes with KEGG pathways. 
 
Section3. Understanding the DNA methylated genes based on stage-specific    
networks 
To understand the significance of the DNA methylated genes for a cancer, stage-
specific networks were obtained using the following steps: 
Identification of gene-gene interactions and DNA methylated-gene interactions 
from BioGRID 
The gene-gene physical association among significant genes and DNA 
methylated genes was identified using BioGRID [25].  This integrated network was 
analyzed across different stages to capture the differences and commonality based on 
the following criteria: (i) two DNA methylated genes interacted; (ii) the DNA  methylated 
gene has interaction with an expressed gene; or, (iii) the DNA methylated gene has 
interactions with a gene other than the significant genes in the given stage. This 
association was termed as “missing link” and the gene as “novel gene”, if the novel gene 
has an interaction with an expressed gene in the given stage or in other stages. Also the 
novel gene was expressed in previous or subsequent stages. This novel gene was then 
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evaluated using biomedical literature for its significance with the DNA methylated gene 
and the given cancer. 
The nodes and the edges of each stage-specific network were annotated with 
their respective topological and biological features. The statistical computing tool R 
(www.r-project.org) was used to compute the topological features betweeness and 
clustering coefficient for each node (gene) in the network. The two biological features 
considered for analysis were: Pathway Significance Score and Gene Ontology Semantic 
Similarity. The Pathway Significance Score was based on the occurrence of the given 
gene in a pathway class i.e., the lung cancer pathways, other cancer pathways, or other 
pathways (includes metabolic) as given in KEGG [24]. These features were normalized 
individually and the average of these features defined the NodeStrength of a node 
(gene), given as: 
               
                                                               
 
 
(i)  
Betweeness of a gene   was defined as the inverse of the ratio of the total number of 
shortest paths from gene s to node t given by     to the number of total paths passing 
through node  (        [26]. This was computed as: 
            (        )   ∑
       
        
 
(ii)  
Clustering Coefficient (Cv) was defined as a function based on the triplets of the genes 
in the network, where a triplet consisted of the three genes (nodes) connected by either 
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two open or three closed undirected ties [27]. The clustering coefficient for the genes in 
the undirected graph (stage- specific network) was computed as: 
 
For a graph         consisting of vertices   and a set of edges  , where      connects 
vertex    vertex    and the neighborhood    for this vertex    was defined as: 
   {          } 
(iii)  
And where    represents the number of vertices in the neighborhood of   . The 
clustering coefficient for this local graph was then computed as: 
                            
   {                    } 
         
 
(iv)  
Pathway Significance Score 
The pathways associated with each node’s   (genes) were identified using KEGG, and 
Pathway Significance Score was computed as; 
                           
  {     [(
                 
               
)                                ]}
        
 
(v)  
Where, Pathway Significance Score for lung cancer case study determined the level of 
importance of a gene in the lung cancer pathways,  non- lung cancer pathways (can be 
other cancer pathways)  and other pathways (i.e. pathways that are not termed as lung 
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cancer pathways or non-lung cancer pathways); frequency of terms equaled the count of 
the gene in lung cancer pathways, non-lung cancer pathways and other pathways; Total 
frequency was equal to the count of the lung cancer pathways, non-lung cancer 
pathways and other pathways; Strength  represented the importance of  the pathway in 
the stage-wise network.  For all the stage-specific network lung cancer pathway was 
given a prior score of 3, non-lung cancer pathways were given a prior score of 2 and 
other pathways were given a prior   score of 1. 
EdgeStrength 
For any two interacting nodes (genes) in the network, EdgeStrength was 
computed based on their Gene Ontology Semantic Similarity. This was calculated using 
the GOSemSim package R [28].  
All the genes and their edges in the stage-specific network were then annotated 
with their NodeStrength and EdgeStrength. The DNA methylated genes were ranked 
based on their NodeStrength. The highly ranked DNA methylated genes were used to 
identify subnetworks as described in the following section. 
Section4. Identification and scoring of epigenetically relevant subnetworks across 
stages 
To understand the functional significance of DNA methylated genes in the 
different stages of cancer, graph techniques were used to identify the subnetworks [29-
31]. To compare and elucidate the interaction network of DNA methylated genes across 
stages is a hard problem. Therefore in this work, subnetworks of different sizes were 
identified and analyzed across the stages to understand the interaction profile of DNA 
methylated genes. As these were open subnetworks i.e. no size and shape limitation, 
therefore an NP-hard problem. To understand these subnetworks functionally, the genes 
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in these subnetworks, were analyzed based on KEGG pathways and these were 
understood in four categories: (i) genes identified in cancer pathways other than lung 
cancer pathways, (ii) genes identified in lung cancer pathways, (iii) genes identified in 
signaling pathways (not present in (i) and (ii), and (iv) genes in the metabolic pathways 
and other pathways. Starting with the DNA methylated gene as a seed, its interactions 
were identified, propagated, and analyzed based on the above four different categories. 
These subnetworks correlate to distinct functions that specify the distinct mechanism 
that can be compared across the stages. These subnetworks were further analyzed 
identified based on their NodeStrength and EdgeStrength.  
The DNA methylated genes in each stage were ranked based on their beta-value. The 
DNA methylated gene with the highest beta-value was considered as a SEED.  The 
SEED and expand algorithm was then used to identify the next connecting gene and 
edge based on the NodeStrength and EdgeStrength. Thus, subnetworks of different 
sizes were identified and connected in each of the stage-specific network and scored 
based on their SubnetworkStrength which was computed as; 
                    
∑                 ∑                     
   
   
               
 
(vi)  
Where,    are nodes,   are edges, and   is number of nodes or edges. 
As this is an open network and subsequently an NP-hard problem, as large 
number of subnetworks of different size are possible. Analyzing these subnetworks 
individually with respect to all its nodes (genes) is both time consuming and hard. 
Therefore, the subnetworks were further classified based on the nodes (genes) that 
were present in the different pathway class, namely, Lung Cancer pathways, Cancer 
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Pathways, Signaling Pathways and Metabolic Pathways.  The subnetworks were 
compared for their commonality and uniqueness across stages to identify the possible 
DNA methylated genes that could be potential targets. The literature was then consulted 
to validate the significance of these DNA methylated genes. 
3.2 Data model for Epigenetics Database      
The data model for epigenetic database was designed based on the requirement 
to hold the results from DNA methylation data processing pipeline and the data obtained 
from different web resources which help to define the epigenetics characteristics of a 
significantly methylated gene. The data model shown in Figure 5 is designed using 
MYSQL workbench[32].  
For analysis results the model holds information such as gene symbol, beta-
value for showing the methylation level of gene in a particular cancer, p-value to 
determine the significance level of the beta-value and stage-wise information. The data 
model also supports information from other important databases such as KEGG 
database[24], some tables from UCSC Genome Browser[33], BioGRID database[25] 
and GO database. KEGG database provide information on the pathways and the 
disease annotation for these pathways along with the information on the environmental 
factors affecting the pathway[24]. This relation was of special importance to the model 
as it helped us to make a connection between the significantly methylated genes, 
pathways they are involved in and the possible environmental factors responsible for the 
current state of genes in the cancer condition. The association helps to distinguish our 
data resource from the present epigenetic data resources. UCSC Genome Browser 
tables help to provide annotations and gene symbol conversions between various data 
sources used in the model[33]. The ID conversion provided by the Genome Browser act 
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as a foreign key between multiple important tables in our database. Whereas BioGRID 
fill in the physical interaction information which helps us to understand the role of 
significantly methylated genes in larger cellular mechanisms and points us to the 
possible area of the cell that needs to be analyzed for better understanding cancer[25].
 
Figure 5 Data model for Epigenetics database 
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3.3 Implementation of Data model for Epigenetics Database 
 
Figure 6 Implementation of Database 
 
 The data model for Epigenetics Database is implemented in 3 layers: Data 
storage layer, Application layer and Client Layer as shown in Figure8. To implement the 
architecture Linux Apache MySQL PHP (LAMP) stack was used.  
Data Storage Layer: 
 Database was implemented using MySQL database management system. The 
database has two interfaces. At first interface the data is dumped into the database as 
shown in Figure6 while at the second interface the data is pulled out of database so that 
it can be displayed by the web application. The query for inserting data in database is: 
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INSERT INTO methylation (gene_name,beta_value,p_value,state,stage,cancer,platform)  
VALUES (   from Python Parser); 
The data from other online data resources was directly imported from text files 
downloaded from these databases. The command used for importing the data from tab 
delimited text files: 
LOAD DATA INFILE 'database.txt' INTO TABLE epigentics_database_table FIELDS 
TERMINATED BY '\t' LINES TERMINATED BY '\n'; 
Application Layer: 
The application layer has 3 main components: Database Interface, Query Engine 
and Web Interface. Database Interface was implemented by forming a connection 
between PHP and database server. In order to make this connection “mysqli_connect ()” 
function from standard PHP library was used by providing proper credentials and the 
database name. Query Engine includes a collection of SQL queries that were used to 
extract relevant information from the database to fulfill various functionalities that are 
made available through interface. Web interface for the application was built using PHP 
and the site is hosted on Linux based server. Additional concepts of web programming 
were used for web interface implementation. Cascading Style Sheets (CSS) were used 
for designing various elements used on web page. Complex logic was implemented by 
making AJAX calls to various web pages. The whole of data storage and application 
layer is present on a server named “Regen” belonging to TiMAP group at IUPUI. 
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 Client layer:   
Client layer involves usage of browsers such as Mozilla Firefox, Google Chrome, 
and Internet Explorer by users to access the web interface from application layer. The 
link to access our web interface: 
 http://regen.informatics.iupui.edu/cgi-bin/epigenetics/DEVenv/index.php 
Through this layer users can select different options that are made available to them 
through web interface. These options then get converted into queries and fetch 
corresponding data from database. These actions are processed by initiating a HTTP 
requests to the server and completed by receiving an appropriate response from web 
server. Apache server application was used to handle HTTP requests from client 
browser, process them appropriately and to respond with a proper HTTP response. 
3.4 Python Parser 
In order to implement the above mentioned DNA methylation data analysis 
pipeline and integrate the results from pipeline to the data model of database, a python 
parser was built to carry out the necessary functionalities.  
The parser has 3 main roles to perform: collect raw data for respective cancer 
type from TCGA data repository, process the collected data through the designed 
pipeline and finally dump the results in the database in the format set by data model. A 
user provides a link for raw data to the parser. After the link is provided the parser 
downloads datasets for the concerned cancer. Along with the link to the raw datasets a 
metadata file containing the stage-wise information for the patients whose data is 
downloaded needs to be provided. Following the downloading step, the parser parses 
the metadata file and segregates the methylation data into different folders according to 
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the stages defined in the file. It generates a tree structure for the files to be stored. The 
topmost node of the folder structure is named with the cancer name. This node is then 
sub-branched into the folders with stage number on them. The automation of this step 
saves the user from the laborious task of manually segregating the dataset files. For 
segregation the parser uses dictionary data structure in which the stage number is 
stored as a key and patient data filenames as values. When it scans the super set of 
datasets it uses this data structure to correctly divide the files in respective stage folders. 
Once the data is segregated correctly, the next step is of data cleaning and merging the 
datasets. At the data cleaning step duplicates are handled in the file by calculating 
median between multiple beta-values for same gene. Once the file is remedied from 
duplicated beta values the data for individual patients is merged and again the folder 
tree structure is further sub-branched into normal and cancer folders. This sub-branching 
happens for each stage present in the cancer.  
 
Figure 7 Python Parser 
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The data is now ready for identifying significant methylated epigenetics genes for the 
cancer. The statistical processing on the dataset was performed by using the 
appropriate statistical packages from R. In order to integrate python parser with R 
environment, system calls are made to the R interpreter from Python code. R provides a 
wide range of flexibility in setting different parameters for the statistical functions present 
in it. Once the analytical steps are performed on the data, the data is molded in a 
template that is consistent with the data model used to store data in epigenetics 
database. As soon as the data is loaded in database and a positive token is received 
from database server, the lifecycle for Python parser is finished. 
3.5 Case Study: LUAD 
The overall methodology for the stage-wise identification of LUAD process 
is shown in Figure 8 that includes four unique steps (A-D).  
 
Figure 8  Methodology to obtain patterns across stages of LUAD 
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Step A: the gene expression data from UNC AgilentG4502A_07_3 was analyzed based 
on the log2 values to obtain the differentially expressed genes.  
Step B: the methylation data from Illumina HumanMethylation27 for each stage was 
analyzed based on the beta value to obtain the differentially expressed methylated 
genes.  
Step C: the data obtained from step A and B was integrated to obtain a stage-specific 
network of LUAD. This network was annotated with the topological and biological 
features and analyzed for methylated pattern identification.  
Step D: the stage-specific subnetworks were obtained for LUAD. Details of each of 
these steps are now described in the following sections.  
Details of each of these steps are provided in the analysis pipeline section. 
Data 
The gene expression and DNA methylation data for LUAD were downloaded from 
TCGA.  The gene expression data were generated by UNC AgilentG4502A_07_3 and 
the methylation profiles were generated by Illumina HumanMethylation27 DNA Analysis 
which contains 27,578 CpG dinucleotides in 14,495 genes[34]. These dataset were 
downloaded on 10-12-2012 and arranged with respect to the four stages of LUAD. 
Across all these stage-wise data, the patient’s age ranged from 58-75 with few outliers. 
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Chapter 4 Results 
The objective of this thesis was to design DNA methylation data analysis pipeline 
and prove the robustness of database as a universal epigenetic analysis result storage 
unit. The database currently holds epigenetically relevant information for: Lung 
Adenocarcinoma (LUAD), Colon Adenocarcinoma (COAD) and Breast invasive 
carcinoma (BRCA). Each cancer has the significant methylated gene information 
segregated in stage-specific manner. The stage specific methylated gene is further 
annotated with data integrated from various other databases to make epigenetic sense 
out of data. Table 12 in Appendix section shows the fields present in databases selected 
for annotations. The table also states reason for selecting particular database for 
annotation of methylated gene. LUAD was considered as a case study to prove the 
effectiveness of pipeline in analyzing DNA methylation data sets to obtain meaningful 
analysis. The TCGA data associated with LUAD was classified based on four stages.  
Across all these stage-wise data, the patient’s age ranged from 58-75 with few outliers.  
4.1 Effectiveness of analysis pipeline  
Identification of highly scored significant DNA methylated genes 
The Significant expressed genes and Significant DNA methylated genes were 
identified based on the p-values and beta-values for each stage as described in the 
methodology.  Resampling technique performed the correction and provided the set of p-
values. Using the technique used in paper [22], p-value of 0.0012 was obtained from q-
values. Using this cutoff the Significant DNA methylated genes were re-evaluated and 
overlap between the previous and resampled results was calculated. A substantial 
amount of overlap between old and new set of Significant DNA methylated genes was 
observed. Figure 16 in Appendix shows the p-value correction for original and corrected 
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Stage I data after resampling.  The DNA methylated genes were then further classified 
as hypermethylated and hypomethylated (methodology section).  Table 8 lists the 
statistics for each stage.  
The significant DNA methylated genes were analyzed and ranked based on their 
beta-values. Table 2 lists the top 10 hyper/hypomethylated genes across stages in 
descending order of their beta-values. 
As shown in Table 2, 10 of the highly methylated genes in Stage I were common 
across the three Stages (Table 1). Of these 10, 7: AJAP1, ATP8A2, HOXA9, PTGDR, 
SIX6, TLX3, TMEM130 were hypermethylated and the three: KRTAP8-1, MMP26 and 
REG3A were hypomethylated. Three of the seven (Stage I) genes: AJAP1, TLX3, 
PTGDR were also identified in Stage III. Interestingly the three top scored 
hypomethylated genes in Stage I were identified as top scored hypermethylated in Stage 
II.  In addition, some of the top scored DNA methylated genes were common across two 
stages only (Table 1): LY96 was the top scored hypomethylated gene and top scored 
hypermethylated in Stage I and II respectively. While HOXA4, HOXD10, KRTAP15-1, 
LEP and NKX6-2 were identified as common across Stage II or III (Table 1). Table 2 
also identified unique top scored DNA methylated genes i.e. 3 for Stage I, 8 for Stage II 
and 13 for Stage III. Comparison of highly DNA methylated genes across stages (Table 
2) with common methylated genes across stages (Table 1) also depicts that a large 
number of the highly methylated genes are common across the stages and these can 
play an important role for understanding the disease. 
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Table 1 Common DNA methylated genes across stages 
Stages DNA methylated genes 
Number List of genes 
Common DNA 
methylated genes 
across the three 
stages 
34 AJAP1, ATP8A2, CCDC140, CNTP2, CYYR1, 
EVX1, FERD3L, FOXG1, GRIK3, GRM6, HAND2, 
HOXA9, HOXB4, HOXD4, HOXD9, HOXD12, 
INPP5B, OTX2, KRTAP8-1, MMP26, PHOX2A, 
PLEKHA6, POU4F2, PRAC, PRKCB, PTGDR, 
REG3A, SIX6, SLC6A2, SPAG6, TBX20, TLX3, 
TMEM130, ZNF560 
Common DNA 
methylated genes 
across Stage I & II 
12 ADCY4, BHMT, C12orf34, CDO1, LVRN, LY96, 
MSC, PCDHGA12, POU3F3, ZNF154, ZNF577, IHH 
Common DNA 
methylated genes 
across Stage II & III 
30 BARHL2, C10orf81, CCDC140, DEFB119, DIO3, 
FAM135B, FAM83A, GRIK2, HOXA4,  HOXD10, 
HS3ST2, KCNS2, KRTAP15-1, LEP, LHX1, LYPD5, 
MAGEB6, NEUROG1, NKX6-2, OR5I1, SERPINB5, 
SPHKAP, TAL1, TBX4, TBX5, TCN1, TMEM132D, 
VSX1, ZNF454, IGKV7-3 
Common 
hypermethylated 
genes across Stage 
I and Stage III 
42 AJAP1, ATP8A2, CCDC140, CNTP2, CYYR1, 
EVX1, FERD3L, FOXG1, FOXI2, GALR1, GAS7, 
GRIK2, GRM6, HAND2, HLA-G, HOXA7, HOXA9, 
HOXB4, HOXD4, HOXD8, HOXD9, HOXD12, 
INPP5B, NID2, NPY, OTX2, PAX7, PHOX2A, 
PLEKHA6, POU4F2, PRAC, PRKCB, PTGDR, SIX6, 
SLC6A2, SOX17, SPAG6, TBX20, TLX3, 
TMEM130, VIPR2, ZNF560 
Common 
hypomethylated 
genes across Stage 
I and Stage III 
3 CORO6, MMP26, REG3A 
 
Table 2 Identification of top beta-value scored DNA methylated genes across stages 
Stage Hyper/Hypo Genes in descending order of beta-values (p<0.001) 
I Hyper TLX3  > NEFM  >  PTGDR  >  AJAP1  >  SIX6  >  HOXA9  
>  TMEM130  > HISTIH3G  >  ATP8A2  > NID2 
Hypo MMP26 > KRTAP 8-1 > REG3A > CORO6 > LY96 
II Hyper LY96 > C10orf81> KRTAP8-1 > MMP26 > REG3A > 
DEFB 119 > NMUR2 > MAGEB6 > IGKV7-3 <  KRTAP15-
1 
Hypo HTR2C > GRIK3 > CNTP2 > SPHKAP > TMEM132D > 
NEFH > LEP > ZNF177 > HOXD10 > NKX 6-2 
III Hyper TLX3 > HOXB4 > AJAP1 > HOXA4 > HOXD9 > PTGDR > 
LYPD5 > FZD10 > HOXD12 > NECAB2 
Hypo CHR6 > C13orf28 > TMEM156 > XDH > FGF6 > IVL >  
G6PC > KRTAP13-2 > C10orf39 > FCRL3 
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Network construction and analysis 
A systems biology approach was used to determine the significance of the DNA 
methylated genes in terms of their associated expressed genes in each stage. The 
interactions between the significant genes (both methylated and non-methylated as 
listed in Table 3), were identified using BioGRID[25] and stage-specific networks were 
constructed. These networks were then annotated with respect to their DNA methylated 
genes.  
Table 3 DNA methylated gene interactions across stages 
Stage Number of DNA methylated genes Number of interactions 
I 72 228 
II 93 273 
III 170 660 
 
The gene interaction analysis showed that each DNA methylated gene also 
interacted with additional genes in BioGRID [25]. These additional genes were analyzed 
for their expression in all the stages to determine if DNA methylation affected their 
expression.  These interactions were termed as “missing links”, and the additional genes 
as “novel genes”. Table 4 gives the profile of the missing links. 
Table 4 Novel genes (Missing Link-methodology) discovered using BioGRID 
Stage Missing 
Links 
Novel 
genes 
Number of DNA 
methylated 
genes 
Number of novel genes and the stages 
where these are identified 
I 27 27 16 6(Stage II, III),6 (Stage II),3 (Stage III) 
II 43 33 25 10 (Stage I, III), 2 (Stage III) 
III 132 83 32 34 (Stage I, II), 3 (Stage I), 7 (Stage II) 
 
Further analysis of the 27 novel Stage I genes for their significance in other stages 
indicated 6 of them in Stage II: ANXA7, APBB1IP, MDK, PFDN1, TINF2, TLE2; 3 in 
Stage III: CUL5, CTNNB1 and SQSTM1 and 6 in Stages II and III: CALM1, CTNNB1,c-
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JUN, SMAD1, TINF2.  Of the 33 novel Stage II genes 2 were associated in Stage III: 
A2M and CTNNB1I; and 10 genes in Stages I and III:  FOXA2, HK3, NCF1, NRIP1, 
PDLIM1, SP1, SUMO1, TCF4, TLR4, and TNN. Analyses of the 83 novel Stage III genes 
found three in Stage I: ELN, FAS and TEX11; 7 in Stage II: ANXA7, APBB1IP, MDK, 
PFDN1, STAT3, TLE2, UBE2B and 34 in Stages I and II:BCR, DLG3m, DLG4, EGFR, 
DSP, MAFF, PICK1 etc.      
  Figure 9 shows the stage-specific networks of DNA methylated genes. From this 
figure it can be seen that Stage III networks were more connected and dense as 
compared to other two stage networks, suggesting the greater number of epigenetically 
modified genes in later stages can influence the LUAD network. 
 
Figure 9 Stage-wise network patterns for methylated genes in LUAD 
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To compare stage-wise networks, DNA methylated gene subnetworks were identified 
and analyzed. Figure 15 in Appendix section shows the distribution of important classes 
of pathway across different stages of LUAD. SEED and expand algorithm (described in 
methods) was used to identify the subnetworks. Table 9 in Appendix list the number of 
subnetworks. These subnetworks were overlapping as the genes in them belonged to 
different pathway class. Table 9 in Appendix shows that the number of subnetworks 
drastically increases between sizes four and five in most of the stages, making it an NP-
hard problem. This sharp increase in the number of sub-network suggests that though 
the DNA methylated gene is not directly connected to a hub node, its interaction path 
has a hub node. This further indicates that a DNA methylated gene can influence the 
whole network of a given stage. Table 5 lists the subnetworks with greater number of 
connections identified in all three stages. 
Table 5 Analysis of hub genes in the DNA methylated subnetworks of size 4 
Stage Sub-network Connectivity profile of the hub node 
across pathways 
Cancer Lung 
cancer 
Signaling Meta-
bolic+ 
others 
I (i) PHOX2A*:HAND2*:PPP2R5D:UBC 
(ii) HLA-G*:COPB1:TRIM37:UBC 
(iii) LY96*:TLR4:SIGIRR:UBC  
23 13 71 288 
 (iv)HLA-G*:COPB1:UBC:CUL1 
(v)FOXG1*:FOXH1:SMAD3:CUL1 
21 14 35 114 
 (vi)HLA-G*:COPB1:UBC:SKP2 19 10 17 38 
II (i)PHOX2A*:c-JUN:SUMO3:UBC 
(ii)TAL1*:HDAC1:IRF5:UBC 
23 14 74 254 
 (iii)PRKCB*:HIST1H3I:CUL4A:CUL1  20 14 74 253 
III (i)PHOX2A*:c-JUN:SUMO3:UBC 
(ii)PHOX2A*:HAND2*:PPP2R5D:UBC  
22 10 64 235 
 (iii)PRKCB*:HIST1H3I:CUL4A:CUL1 20 13 35 102 
  *: commonality with Table 1 
As shown in Table 5, UBC and CUL1 were identified as hub gene across the 
three stages and their connectivity profile changes with pathway class. The other hub 
genes (number of connections) identified in Stages I and III were: SIRT7 (6), CDK2 (5), 
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PMS2 (4 connections), SUMO2 (3), SMAD3 (7), SMAD4 (5), and SMAD2 (4). The 
analysis also identified LY96 sub-network in Stage I consisting of the hub gene TLR4 
interacting with seven other genes. Though LY96 was also identified in Stage II, the 
comparative sub-network was smaller and this gene was not identified at all in Stage III. 
HLA-G was present in Stage I but not in Stage II; therefore all its sub-networks were 
missing. In Stage II and III, c-Jun a TF was identified as a hub gene. PHOX2A was the 
DNA methylated gene associated with c-Jun in both stages.  There was similarity across 
common gene (see Table 1) with Table 6, depicting that subnetworks constructed out of 
common genes across or between two stages can be of significance for LUAD.  The size 
four subnetworks were further compared across the stages to understand their 
commonality and uniqueness (Table 10 in Appendix). These size four subnetworks were 
analyzed for their common DNA methylated genes. The common DNA methylated 
genes in these size four subnetworks present across cancer, lung cancer and signaling 
pathway classes were FOXG1 and PHOX2A (see in Table 1 also). The other common 
significant but not methylated genes present in these subnetworks were FOXH1, 
FOXO3, HAND2, MYC, RB1, SMAD2, SMAD3, SMAD4, and TP53. The unique genes in 
these subnetworks that were associated with other cancer and lung-cancer pathways 
were LEF1, AR, GATA4, and SKP2. Similarly, in the metabolic pathways class, the 
highly conserved common sub-networks of GRIK2, GRIK3, GRIK5, and GRID2 were 
identified across all stages. Of these GRIK3 was methylated in all the three stages 
(Table 1) and GRIK2 in Stages I and III (Table 1).   
Analysis of these subnetworks is an NP-hard problem because these are large 
open subnetworks.  To reduce the complexity, the nodes and edges were scored based 
on the NodeStrength and EdgeStrength as given in methods section. The top scored 
size four subnetworks of each stage (Table 5 and Table 9 in Appendix) were propagated 
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and compared to identify the largest conserved subnetworks across the stages. This 
analysis identified a sub-network of size 11 with seven conserved genes: UBC, KRAS, 
PIK3CA, PIK3R3, RAF1, BRAF, and RAP1A.  The g:Profiler tool was used for the  
enrichment analysis on the top scored sub-network given in Table 6.  This analysis 
showed that these subnetworks to be enriched with common genes across stages 
(shown in Table 1), indicating that commonality across stages of LUAD can be critical in 
identifying the target genes.  
Table 6 Enrichment analysis of the top scored subnetworks 
Stage Biological Process p-value  Genes in subnetworks 
Common 
across 
all 
Stages 
Activation of MAPKK 
activity 
1.12E-03 PHOX2A*, HAND2*, 
PPP2R5D, UBC, KRAS, 
PIK3CA, PIK3R3, RAF1, 
BRAF, RAP1A 
I & II Co-SMAD binding 1.2E-05 FOXG1*, FOXH1, 
SMAD2, SMAD1, 
MED15, UBC, KRAS, 
PIK3CA, PIK3R3, RAF1, 
BRAF, RAP1A 
II & III Nerve growth factor 
receptor signaling 
pathways 
2.21E-04 HOXD4*, INPP5B, 
SLC6A2, STX1A, 
VAMP1, UBC, KRAS, 
PIK3CA, PIK3R3, RAF1, 
BRAF, RAPIA 
I & III Positive regulation of 
peptidyl-serine 
phosphorylation 
1.42E-03 NPY*, NPY1R, LSM7, 
NR1H2, RMI1, UBC, 
KRAS, PIK3CA, PIK3R3, 
RAF1, BRAF 
I Transmembrane 
receptor protein 
tyrosine kinase 
signaling pathway 
1.87E-03 HLA-G*, COPB1, UBC, 
KRAS, PIK3CA, PIK3R3, 
RAF1, BRAF, RAP1A 
II DNA helicase 
complex 
6.8E-05 SERPINB5*, UCHL5, 
ACTR8, ACTR5, UBC, 
KRAS, PIK3CA, PIK3R3, 
RAF1, BRAF 
III Nerve growth factor 
receptor signaling 
pathway 
5.5E-04 HOXB4*, CREBBP, 
KLF13, UBC, KRAS, 
PIK3CA, PIK3R3, RAF1, 
BRAF, RAP1A 
 *: commonality with Table 1 
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4.2 Database statistics 
In order to avoid the loss of methylation data due to statistical stringency, the data 
entering the database skips the q-value filter for the p-values. This allows a researcher 
to select a data filtration of his/her choice in downstream processing based on the p-
values provided through the database interface. The statistics shown in table 7 varies 
from the statistics in table 8 for LUAD because of the q-value filtration.       
Table 7 Distribution of methylated genes for cancer data in database 
 LUAD COAD` BRCA 
 Hyper Hypo Hyper Hypo Hyper Hypo 
Stage1 134 21 507 441 0 0 
Stage2 108 39 685 241 391 137 
Stage3 231 119 616 340 208 124 
Stage4 0 0 0 0 - - 
   
The methylated stage specific genes are annotated with following data: 
1. Gene name 
2. Beta value 
3. P value 
4. State 
5. Stage 
6. Pathway 
7. Go Terms 
8. Interaction 
9. Disease 
The disease column is further connected to “Environmental Factors” responsible for 
inception of the disease. This is an important link as the knowledge of “Environmental 
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Factors” is a key point in understanding the variation of methylation levels based on the 
external factors. 
Table 8 Distribution of significant genes and methylated genes across the four stages of 
LUAD 
4.3 Database Interface    
 Epigenetics database can be queried using a combination of 3 options that are 
presented at the homepage of the interface for the database. Figure 10 shows the home 
page of the website for the database. The left panel on the page has external links to 
additional electronic resources of epigenetic data. Central panel holds the searching 
capability. First the user can select from the list of cancer types that are currently present 
in the database. Based on the cancer type associated stages get populated into the 
“Select Stage” dropdown. From the options displayed, one can select information for 
individual stages or can call for a combined result set of all stages present in the 
selected cancer.  The third option provides the usability of filtering the result set on the 
basis of state of the gene whether it is hyper or hypo methylated. User can also choose 
to obtain a combined result set of hyper/hypomethylated genes for a cancer type and its 
stage. 
Stage Number of 
Normal 
Samples 
Number of 
Disease 
Samples 
Significant 
Genes 
DNA Methylated 
Genes 
Hyper Hypo 
I  9 35 15994 67 5 
II 7 14 16275 20 73 
III 5 11 14688 110 60 
IV 2 6 14814 0 0 
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Figure 10 Home page for Epigenetics Database 
 
Figure 11 shows the LUAD result table filtered for hypermethylated genes in 
Stage 1 of cancer. Each gene in the table is characterized both statistically and with 
epigenetic relevant information. The statistics includes beta and p values for a 
methylated gene. These measures can be used by researchers to set up their own 
downstream processing experiments and derive results or networks for their respective 
researches. Beta values also state the methylation level of the genes in that specific 
cancer whereas the p-values state the statistical significance of the methylation level 
which is based on Mann Whitney test. Other epigenetically associated parameters such 
as pathways, GO terms, interactions and disease information help in understanding the 
role and nature of gene which can be used to make inferences for treating them.          
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Figure 11 Result Table for options selected for query engine 
 
 The most important association of the database is shown in Figure 12. It shows 
the relationship between a gene, pathways it is present in and the disease caused by its 
malfunctioning. Disease field is then related to the environmental factors that may be 
responsible for the aberration of a gene’s normal function. This loop completes the basic 
requirement of an epigenetic study which is the role of environmental factors in 
controlling the activity of a gene. Finally Figure 13 and 14 show the tables with GO terms 
and physical interactions for a gene. These tables help to elucidate the functions and 
interacting genes that may be affected by the methylation of a gene and can provide a 
local target for understanding the molecular working of a cancer.   
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Figure 12 Relationship between gene, pathway, disease and factors causing the 
disease 
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Figure 13 GO Terms associated with a methylated gene 
 
 
Figure 14 Interactions for a particular gene 
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Chapter 5 Conclusion 
Our work proved the importance of integrating methylation data with the 
expression data for finding the patterns in a cancer. It showed the robustness of pipeline 
built for identifying key patterns which were helpful for distinguishing stages within a 
cancer and understanding critical targets for drug treatment. In addition to pipeline the 
data model used to store the meaningful data from analysis uses a sound parser, 
emphasizes the application of process automation and data warehousing for 
epigenetics.  
The DNA methylation epigenetics data analysis pipeline is entirely based on the 
available TCGA data, which has the limitation of unequal samples, still we were able to 
prove the advantage of integrating epigenetic data, expression data and protein-protein 
interaction knowledge for advancing of systematic understanding of LUAD. This 
understanding can be further improved by incorporating the system biology approach to 
the epigenetic profile across the different stages of cancer data. This study’s detailed 
analysis of epigenetics genes identified 72, 93 and 170 epigenetic genes across Stages 
I, II and III of LUAD. A set of 32 common epigenetic genes was identified across the 
three stages, and it was observed that methylation patterns were similar across Stages I 
and III, but were different in Stage II. The study also identified known and novel 
epigenetic genes across stages that were important   in LUAD, these genes could be 
further validated in the laboratory for their scope as targets. The novel epigenetic genes 
identified were PTGDR, POU4F2, TLX3, and MMP26 along with these genes study 
identified early and late expression profiles of NEUROG1, AJAP1, and CORO6 in LUAD. 
System biology approach stated that epigenetic genes were not the hub nodes but could 
still affect the hub genes in the networks, eventually playing a critical role in the disease 
mechanism. Subnetworks of size 11 with 7 conserved genes across the three stages 
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were all literature validated, confirming their importance in LUAD. Therefore, it can be 
concluded that integrating epigenetic genes with expression data can be useful for 
comprehending in-depth disease mechanism and for the ultimate goal of better target 
identification. 
The data model built to house the analysis results has a structure capable of 
managing the current input of data with flexibility to incorporate future changes which will 
come by integration of sequencing data. Currently the database holds analysis results 
for 3 cancers: Lung adenocarcinoma (LUAD), Colon adenocarcinoma (COAD) and 
Breast invasive carcinoma (BRCA). The web interface for this cancer results provides a 
structure and data which is more epigenetically meaningful compared to other databases 
which just display experimental data rather than compiling them in a way which makes 
sense to lot of scientist. Our database and its interface is designed in both simplistic as 
well as deep way that it will help a novice in the field to have it as its starting point and 
act as a support mechanism for a seasoned epigenetics analyst. The interface helps a 
user to query our database with multiple options which include a combination of 3 fields: 
cancer type, cancer stage and state of the genes. A user can select one of the cancer 
types that are currently available in our database and accordingly can select one of the 
stages or information on all stages. Once the cancer type and stage is selected an 
additional filter of methylation state is made available which helps them to extract genes 
whose state can be hypermethylated or hypomethylated. This provides the depth and 
granularity of analysis which is often required in understanding the epigenomics 
landscape of any cancer. On selecting above mentioned options a result table is 
displayed with multiple fields explaining the epigenetic parameters affected in that 
cancer. Beta-value field provides quantitative measure for a gene to determine its state 
in a cancer which can be either hyper or hypomethylated. The p-value field provides the 
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statistical significance measure which helps researchers to infer the qualitative meaning 
of beta-values. Additional fields such as Pathways, GO terms, Interactions and Disease 
help in understanding the relationship of gene with other cellular components covering 
most of the factors which can have influence on the activity of gene fulfilling the most 
important requirement of any epigenetic study. The disease field throws light on the role 
of gene in other diseases which brings in the additional information on the ways to tackle 
the gene aberration. Environmental factors field having the factors affecting the gene in 
a particular disease form help us to link these factors back to the state of gene in cancer. 
Thus our database provides a holistic view of DNA methylation epigenetic state of all 
affected genes in a particular cancer. 
Hence using the pipeline developed through this thesis work and the data model 
designed to store the analysis results a researcher can create an experimental 
framework for any cancer study that he wishes to understand. The interface for database 
has a visual display which is created by a compilation of the fields that bring more 
epigenetic sense to the methylation data. Integration of methylation and expression data 
in the pipeline identifies important patterns and key targets which can help in prognosis 
of variable stages in cancer. The pipeline in conjunction with database can be utilized to 
design a strong architecture to detect the signs of aberrant DNA methylation of gene 
which can help in early detection of cancer.           
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Chapter 6 Discussion 
Current epigenetic resources lack important parameters which make it difficult for 
researchers to picture a complete epigenomics working for any cellular machinery 
involved in cancer. There are numerous analysis pipelines available to analyze 
epigenetic data making it difficult to integrate them. We provide a solution to these 
problems by developing a universal pipeline not only to obtain significant methylated 
genes but to identify progressive methylation patterns present in different stages of any 
cancer. Although our pipeline was built using TCGA datasets, it can be extended to any 
platform providing beta-values and log2 ratios for the genes involved in cancer. The 
parser gives a great advantage in automating the execution of pipeline and saves the 
laborious tasks which often lead to human error.  
Our pipeline for LUAD as a case study showed that the maximum number of 
DNA methylated genes was identified for Stage III followed by Stage II and then Stage I. 
None of the genes in Stage IV met the filtering criteria; therefore, no genes were 
identified as DNA methylated. From Table 1, it can be seen that hypermethylated genes 
were more prevalent in Stages I and III than in Stage II. Though this study identified 34 
common DNA methylated genes (see Table 2) across the three stages, many of these 
have not been previously studied in LUAD. The HOX genes that were common across 
the three stages are TFs and grouped into four HOX families, A, B, C, and D; equivalent 
numbered HOX genes (HOXA9, HOXB9) in each family groups (A, B, C, D) are 
paralogs.  The analysis found HOXA4, HOXA9, HOXB4, HOXD9, and HOXD12 genes 
with high methylation value, suggesting these genes play an important role in all stages 
of LUAD. These genes are known to be involved in cell proliferation while preventing 
apoptosis and help in survival [35], dysregulated behavior of HOX genes has been  
observed in ovarian cancer [36]. Early stage HOXA9 methylation has been identified in 
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lung cancer and used in early detection and prognosis [37, 38]. Our analysis found HOX 
genes in all stages, with hypermethylation in Stages I and III, hypomethylation in Stage 
II. While no previous studies have associated the profile of HOX genes with stages, 
though re-appearance was identified and our analysis demonstrated this aspect. Another 
gene identified by our analysis across all three stages was PTGDR, which was highly 
hypermethylated in Stages I and III (Table 1). PTGDR has been negatively correlated 
with smoking [39] and methylated in colon cancer [40], however, prior studies have not 
investigated its role in LUAD.  POU4F2 and TLX3 were identified in all three stages   and 
TLX3 was highly methylated in Stages I and III (Table 1). Previous studies have found 
them as methylated in leukemia and breast cancer respectively [41, 42] but not in LUAD.  
Overexpression of TBX20, which was also identified in this study (see Table 1) has been 
reported in lung cancer [43]. EVX1 and OTX2 (see Table 2) were identified as 
methylated in NSCLC and lung cancer [44, 45].  MMP26 has been associated with tumor 
development, invasion and metastasis of NSCLC but its methylation profile was not 
reported [46], our analysis showed it to be highly hypomethylated in Stage II (Table 1). 
There was no literature evidence about KPTAP8-1, REG2A, and SLX6 for their 
significance or methylation in lung cancer.  
Of the 12 common methylated genes common to Stages I and II, LY96 has been 
previously associated with lung cancer [47]; ZNF577 and LVRN  has been identified as 
methylated in lung cancer [45] and renal carcinoma, but not in LUAD [48].  LY96 was 
highly hypomethylated in Stage I and hypermethylated in Stage II (as shown in Table 1), 
suggesting further investigation into its role in LUAD. 
In addition to pipeline the data model for database is only designed to capture 
the DNA methylation aspect of epigenetic study. In order to be called as epigenetic 
database the coverage needs to be extended to other wings of epigenetics which 
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include concepts such as histone modifications and data on chromatin remodeling. But 
the model provides a complete solution for DNA methylation data. It covers all important 
aspects that are needed for a researcher to understand the problem and provides 
sufficient fields to come with possible cure. The initial version of database was aimed to 
tackle the major epigenetic sub-type which is DNA methylation. Fields such as 
pathways, go terms, interactions are considered to be important factors affected by DNA 
methylation aberration. Understanding the relation between other cellular components 
can throw light on the role of affected gene and its cause of variation from normal state. 
The field for environmental factors included from KEGG database [24] includes the basic 
requirement for epigenetics analysis which most of the data resources in this sector fail 
to include in their data model. It laid a foundation which has given a way to a framework 
which can be used to include different data structures required to process different types 
of epigenetics data.     
Thus the combination of analysis pipeline, parser implementing the pipeline and 
the data model housing the analysis results can be used for efficient processing of any 
DNA methylation epigenetic data.  
 
 
 
 
 
 
  
51 
  
Chapter 7 Future Work 
Inclusion of other epigenetics branches such as histone modifications and 
chromatin remodeling data analysis forms the major task for the future work of our 
epigenetics system. We also wish to include sequence data which seems to be the 
future form for any kind of scientific data that would be available for analysis. For data 
model, it will be extended to accommodate these new forms of data that would be 
coming from the new pipelines designed. The interface will have more epigenetics 
analysis tools which researchers can use to analyze their datasets. The pipeline parser 
would also be made available through interface so that it can be used by researchers to 
automate their experimental analysis. We also wish to integrate various visualization 
tools such as Cytoscape [49] and Circos [50] through our interface which would help in 
visualization of analysis results.   
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Chapter 9 Appendix 
9.1 Pathway Distribution across stages for LUAD 
 
Figure 15 Pathway Distribution 
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Table 9 Pathway distribution according to sub-network sizes 
Stage Sub-
network 
Size 
Pathway distribution 
Cancer Lung cancer Signaling Metabolic +others 
I 2 1 - 3 5 
 3 4 1 5 10 
 4 68 45 175 568 
 5 2685 1466 5072 1263 
II 2 3 1 2 6 
 3 58 19 69 107 
 4 1176 532 2049 4230 
 5 31982 15884 59137 133380 
III 2 3 1 3 7 
 3 80 33 95 155 
 4 1476 679 2578 5952 
 5 141149 19951 76205 175691 
 
Table 10 Analysis of common and unique sub-networks of size 4 revealing the 
significant genes 
Pathway Stages 
I & II & 
III 
I & II I & III II & III I II III 
Cancer 18 4 43 820 - 336 591 
Lung cancer 11 - 25 369 - 153 274 
Signaling 70 2 222 1372 27 641 1049 
Metabolic + 
others 
74 - 792 2844 135 1347 2677 
 
 
Table 11 DNA methylated genes in UBC subnetworks across stages 
Stage UBC interaction with methylated genes 
I FOXG1, GAS7, HLA-G, HOXD8, LY96, MSC, NPY, PHOX2A 
II ACTN2, CDO1, FOXG1, HOXA1, HOXD4, HTR2C, INPP5B, LHX1, 
NEFH, OTX2, PHOX2A, PRKCB, SERPINB5, SLC6A2, SRGN, and 
TAL1 
III ATP6VOD2, CFTR, CRMP1, DGKI, EPO, FLG, HAND2, HOXA7, 
HOXB4, HOXD4, HOXD12, IHH, INPP5B, NECAB2, NEUROG1, NPY, 
PDZRN3, POU3F1, PHOX2A, SGMS2, SLC6A2, SPTA1, TBX5, 
TMEM132D, WNK2 and XDH 
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9.2 P-value correction-before and after resampling and bootstrapping 
 
Figure 16 Resampling p-value correction 
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9.3 Epigenetic Data Annotation 
Table 12 Functional annotation 
Database Fields in Database Reason for selecting DB 
BioGRID  interactor_A 
 interactor_B 
 synonyms_interactor_A 
 synonyms_interactor_B 
 experiment_type 
 score 
 source_database 
BioGRID database 
provides information on 
physical interactions for 
methylated genes which 
can be used to understand 
the network of genes in a 
particular cancer. 
GO database 
(gene2go) 
 entrezid 
 go_id 
 go_term 
GO database provided the 
functional annotations to 
the gene. 
KEGG 
(KEGG_disease) 
 Entry 
 Name 
 Description 
 Category 
 Pathway 
 Gene 
 Env_factor 
Disease table from the 
KEGG database is used to 
include information on 
disease caused due to 
malfunctioning of pathways 
and environmental factors 
responsible for disease. 
KEGG 
(KEGG_gene_pathway) 
 name 
 pathway_id 
 entrezid 
Gene-pathway table from 
KEGG helps to extract 
pathways affected by the 
gene 
Entrez 
(Entrez2gene) 
 entrezid 
 gene 
Entrez2gene table is used 
for mapping entrezid to 
human readable gene 
symbols.  
UCSC genome browser 
(UCSC2GeneSymbol) 
 kgid 
 genesymbol 
UCSC2GeneSymbol table 
is used for mapping keg 
gene ids to human 
readable gene symbols. 
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